[ CrossRef ] [ Google scholar ] [ PubMed ] Meng S, Chanda P, Thandavarayan RA, Cooke JP
Gland Pharma Limited FY25 Results: Margins Hold Strong, Strategy Gathers Steam Financial Highlights: - FY25 Revenue: 5,617 Cr (1% YoY) - EBITDA Margin: 1,269 Cr (5% YoY) | Margin 23% - PAT: 698 Cr (10% YoY) | Margin at 12% - Dividend: 18/share final dividend recommended Business Highlights: - 31 product launches in FY25, including new molecules like Latanoprost & Dexamethasone - 32 ANDA approvals, 24 filings U.S
3.2.2 Randomized controlled trials of the effect of the MedDiet on obesity and inflammation Observational studies frequently include large cohorts for statistical power but randomized controlled trials (RCTs) add a layer of rigor and control to the results, moving us closer to determining the cause of the investigated effect
Your doctor probably told you to stop taking it for a little while
Interacciones farmacolgicas
13 Mei 2024 Apakah Anda mencari cara lezat untuk meningkatkan kesehatan Anda